Back to discover
Drug

Retatrutide

Late-stage clinical development
ClassGlucagon-like peptide 1 receptor agonist
RxNorm2722410ChEMBLCHEMBL5095485UNIINOP2Y096GV
13
Active clinical trials
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

'Gray Market' Retatrutide Study; Menopause and the Brain; Drug Allergy Warnings

Research2026-08-25Research news · MedPage Today

GLP-1s and Birth Control; Retatrutide Lawsuits; Air Pollution and Menopause

Industry2026-08-18MedPage Today — Endocrinology

STAT+: Eli Lilly targets booming black market for retatrutide

Industry2026-08-13STAT News

A Phase 3, Randomized, Multicenter, Open-label Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Semaglutide Once Weekly in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Metformin With or Without SGLT2 Inhibitor (TRANSCEND-T2D-2)

Clinical trial2026-08-01Primary completion · ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Clinical trial2026-07-20Results expected Q1 2029 · ClinicalTrials.gov

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

Clinical trial2026-07-17Results expected Q3 2030 · ClinicalTrials.gov

A Phase 1, Investigator- and Participant-Blinded Study to Evaluate the Effect of Retatrutide on α- and β- Cell Function and Insulin Sensitivity in Adult Participants With Type 2 Diabetes Mellitus

Clinical trial2026-07-16Status changed to Active, not recruiting · ClinicalTrials.gov

STAT+: Lilly’s retatrutide has been offered to a single person via ‘compassionate use’ program

Industry2026-06-23STAT News

ADA: Novo’s Lange says ‘jury still out’ on CagriSema amid tough retatrutide comparisons

Industry2026-06-10Fierce Biotech

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Clinical trial2026-06-09Results expected Q4 2028 · ClinicalTrials.gov

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Clinical trial2026-05-20Results expected Q3 2027 · ClinicalTrials.gov

A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

Clinical trial2026-05-04Completed · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Retatrutide
RxNorm CUI
2722410
ChEMBL ID
CHEMBL5095485
UNII
NOP2Y096GV
Primary mechanism
Glucagon-like peptide 1 receptor agonist

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

Glucagon-like peptide 1 receptor
GLP1R · P43220
AGONISTGlucagon-like peptide 1 receptor agonist
Glucagon receptor
GCGR · P47871
AGONISTGlucagon receptor agonist
Gastric inhibitory polypeptide receptor
GIPR · P48546
AGONISTGastric inhibitory polypeptide receptor agonist

Clinical trials

19 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
19
registered trials across all phases
LATEST COMPLETION 2026
13
Active studies
3
Recruiting
14
Late-stage (III+)
6
Completed
PHASE DISTRIBUTIONn = 19
Phase 13Phase 22Phase 314

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

A Master Protocol for a Randomized, Controlled, Clinical Trial of Multiple Pharmacologic Agents in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease Who Are at Increased Risk of Developing Major Adverse Liver Outcomes

RecruitingPH IIIKey trialEli Lilly and Companyn=4,5002032

A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Investigate the Effect of Retatrutide on the Incidence of Major Adverse Cardiovascular Events and Major Adverse Kidney Events in Participants With Body Mass Index ≥27 kg/m2 and Atherosclerotic Cardiovascular Disease and/or Chronic Kidney Disease

Active, not recruitingPH IIIKey trialEli Lilly and Companyn=10,0002029

A Phase 3b Study to Investigate the Efficacy and Safety of Different Retatrutide Dose Escalation Schemes in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Controlled, Double-Blind Trial

Active, not recruitingPH IIIEli Lilly and Companyn=6002028

A Phase 3b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Retatrutide Treatment in the Maintenance of Weight Reduction in Individuals With Obesity

Active, not recruitingPH IIIEli Lilly and Companyn=6432028

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

RecruitingPH IIIEli Lilly and Companyn=5862027

Recent completions

Trials that read out recently, adding to the completed evidence base.

A Randomized, Placebo-Controlled, Parallel Study to Investigate the Response of Participants With Type 2 Diabetes Mellitus on Once-Weekly Retatrutide to Hypoglycemia

CompletedPH IEli Lilly and Companyn=802026

A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)

CompletedPH IIIKey trialEli Lilly and Companyn=2,3352026

A Phase 3, Randomized, Multicenter, Double-Blind Study to Investigate the Efficacy and Safety of Retatrutide Once Weekly Compared With Placebo in Adult Participants With Type 2 Diabetes and Inadequate Glycemic Control With Diet and Exercise Alone (TRANSCEND-T2D-1)

CompletedPH IIIEli Lilly and Companyn=5372026

A Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Who Have Obesity or Overweight and Osteoarthritis of the Knee: A Randomized, Double-Blind, Placebo-Controlled Trial

CompletedPH IIIEli Lilly and Companyn=4452025

A Phase 2b, Double-Blind Study to Investigate the Effect of Retatrutide on Renal Function in Participants With Overweight or Obesity and Chronic Kidney Disease With or Without Type 2 Diabetes

CompletedPH IIEli Lilly and Companyn=1462025

A Phase 1, Open-label, Single-arm Study to Investigate the Effect of Retatrutide on Metoprolol Pharmacokinetics in Healthy Participants

CompletedPH IEli Lilly and Companyn=302025
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials